AWM
REGN icon

Avitas Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Avitas Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$265K Buy
372
+42
+13% +$35.2K 0.04% 184
2024
Q3 		$347K Sell
330
-24
-7% -$26.7K 0.05% 179
2024
Q2 		$372K Sell
354
-20
-5% -$19.4K 0.05% 179
2024
Q1 		$360K Sell
374
-8
-2% -$7.61K 0.05% 188
2023
Q4 		$336K Sell
382
-149
-28% -$123K 0.06% 179
2023
Q3 		$437K Sell
531
-19
-3% -$14.9K 0.08% 170
2023
Q2 		$395K Sell
550
-7
-1% -$5.4K 0.07% 169
2023
Q1 		$458K Sell
557
-20
-3% -$15.1K 0.09% 160
2022
Q4 		$416K Buy
577
+2
+0.3% +$1.48K 0.09% 155
2022
Q3 		$396K Buy
575
+2
+0.3% +$1.26K 0.09% 148
2022
Q2 		$339K Buy
+573
New +$372K 0.07% 162
2021
Q1 		– Sell
-6,918
Closed -$3.34M – 225
2020
Q4 		$3.34M Buy
6,918
+334
+5% +$180K 0.68% 44
2020
Q3 		$3.69M Buy
6,584
+45
+0.7% +$27.3K 1.03% 24
2020
Q2 		$4.08M Sell
6,539
-1,092
-14% -$620K 1.35% 16
2020
Q1 		$3.73M Buy
+7,631
New +$3.15M 1.7% 12
2019
Q2 		– Sell
-7,350
Closed -$3.02M – 176
2019
Q1 		$3.02M Buy
+7,350
New +$3.03M 0.88% 45

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avitas Wealth Management's REGN Position: Q4 2024 in Review

Avitas Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 13% in Q4 2024, buying an estimated $35.2K and bringing the position to 372 shares worth $265K. The position accounts for 0.04% of the portfolio, ranked #184.

Avitas Wealth Management first reported a position in REGN in Q1 2019 and has held it in 16 quarters since. The position peaked at $4.08M in Q2 2020. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Avitas Wealth Management held 372 shares of Regeneron Pharmaceuticals worth $265K as of Q4 2024.
  • Avitas Wealth Management bought 42 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $35.2K.
  • Regeneron Pharmaceuticals made up 0.04% of Avitas Wealth Management's portfolio in Q4 2024, its #184 holding.
  • Avitas Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 16 quarters since.
  • Avitas Wealth Management's Regeneron Pharmaceuticals position peaked at $4.08M in Q2 2020.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Avitas Wealth Management's 13F filing for Q4 2024, filed 27 Jan 2025.